- Home
- EDIT vs ELMD Comparison
EDIT vs ELMD Comparison
Compare EDIT & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | ELMD |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 199.2M |
| IPO Year | 2016 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EDIT | ELMD |
|---|---|---|
| Price | $2.64 | $23.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.92 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.6M | 94.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.50 | ★ 46.55 |
| EPS | N/A | ★ 0.56 |
| Revenue | $31,937,000.00 | ★ $54,716,000.00 |
| Revenue This Year | N/A | $15.59 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ N/A | $42.55 |
| Revenue Growth | ★ 132.64 | 13.83 |
| 52 Week Low | $0.91 | $17.73 |
| 52 Week High | $4.54 | $30.73 |
Technical Indicators
Market Signals| Indicator | EDIT | ELMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 40.90 |
| Support Level | $2.42 | $23.38 |
| Resistance Level | $2.76 | $25.52 |
| Average True Range (ATR) | 0.19 | 0.96 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 87.56 | 37.61 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.